Active, not recruitingPhase 3NCT04666610
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Studying Childhood absence epilepsy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- UCB Biopharma SRL
- Principal Investigator
- UCB Cares001 844 599 2273 (UCB)
- Intervention
- Brivaracetam(drug)
- Enrollment
- 153 enrolled
- Eligibility
- 2-25 years · All sexes
- Timeline
- 2021 – 2026
Study locations (30)
- N01269 115, Birmingham, Alabama, United States
- N01269 105, Orange, California, United States
- N01269 116, Denver, Colorado, United States
- N01269 111, Miami, Florida, United States
- N01269 101, Tampa, Florida, United States
- N01269 104, Winter Park, Florida, United States
- N01269 110, Augusta, Georgia, United States
- N01269 100, New Brunswick, New Jersey, United States
- N01269 109, Winston-Salem, North Carolina, United States
- N01269 106, Philadelphia, Pennsylvania, United States
- N01269 400, Tbilisi, Georgia
- N01269 401, Tbilisi, Georgia
- N01269 402, Tbilisi, Georgia
- N01269 403, Tbilisi, Georgia
- N01269 405, Tbilisi, Georgia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04666610 on ClinicalTrials.govOther trials for Childhood absence epilepsy
Additional recruiting or active studies for the same condition.